Recent studies showed that CDH5 levels and CDH5 glycosylation are biomarkers for metastatic breast cancer (Fry et al., 2016) and TRIB1 plays a critical role in cell cycle and survival via NF-κB signaling (Gendelman et al., 2017). Here, CDH5 is linked to breast carcinoma.